October 9, 2023ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsAssays monitoring circulating tumor DNA (ctDNA) have the potential to predict early resistance to immunotherapy and allow for early intervention. Read more »
October 19, 2023White Paper: Tissue Handling and Stewardship Recommendations for OmniSeq INSIGHT® Testing – A Pre Analytical Approach to Comprehensive Genomic Profiling Download White PaperAuthors: Read more »
October 1, 2023Molecular Tumor Board: 56 year-old female with Stage IIIC2 endometrial cancer, PD-L1 <1%, MSI-H, TMB-H Read more »
June 7, 2023Molecular Tumor Board: 48 year-old female with cutaneous melanoma harboring NRAS Q61R mutationPresent Read more »
June 7, 2023Molecular Tumor Board: 64 year-old female with recurrent breast cancer and PIK3CA mutationPresented b Read more »
October 5, 2023Healthcare access dimensions and uterine cancer survival: A National Cancer Database study Read more »
September 23, 2023PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes Read more »
September 14, 2023Molecular Tumor Board: 77 year-old female with a history of ER+/PR+/HER2- right breast cancer and new lung mass with EGFR exon 19 deletion and ALK fusion Read more »
